🏢CompaniesEyePoint Pharmaceuticals Shares Phase III Trial Results for Retinal Drug DURAVYU
EyePoint Pharmaceuticals executives discussed recent Phase III clinical trial outcomes for its flagship retinal disease treatment, DURAVYU, at the UBS Global Biopharma Co…